0001213900-21-063810.txt : 20211207 0001213900-21-063810.hdr.sgml : 20211207 20211207094351 ACCESSION NUMBER: 0001213900-21-063810 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211207 DATE AS OF CHANGE: 20211207 EFFECTIVENESS DATE: 20211207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pasithea Therapeutics Corp. CENTRAL INDEX KEY: 0001841330 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851591963 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-423899 FILM NUMBER: 211474874 BUSINESS ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 BUSINESS PHONE: 8184226172 MAIL ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 D 1 primary_doc.xml X0708 D LIVE 0001841330 Pasithea Therapeutics Corp. 1111 LINCOLN ROAD SUITE 500 MIAMI BEACH FL FLORIDA 33139 (702) 514-4174 DELAWARE None None Corporation true 2020 Lawrence Steinman 1111 Lincoln Road Miami Beach FL FLORIDA 33139 Director Simon Dumesnil 1111 Lincoln Road Miami Beach FL FLORIDA 33139 Director Yassine Bendiabdallah 1111 Lincoln Road Miami Beach FL FLORIDA 33139 Executive Officer Director Stanley M. Gloss 1111 Lincoln Road Miami Beach FL FLORIDA 33139 Executive Officer Tiago Andre Dos Reis Marques 1111 Lincoln Road Miami Beach FL FLORIDA 33139 Executive Officer Director Emer Leahy 1111 Lincoln Road Miami Beach FL FLORIDA 33139 Director Biotechnology Decline to Disclose 06b false 2021-11-29 false true true true false 0 EF Hutton, division of Benchmark Investments, LLC 103792 None None 590 MADISON AVENUE 39TH FLOOR NEW YORK NY NEW YORK 10022 CA CALIFORNIA CT CONNECTICUT FL FLORIDA NV NEVADA NJ NEW JERSEY NY NEW YORK PR PUERTO RICO false 30380000 30380000 0 The securities were issued in an offering of 8,680,000 shares and 8,680,000 warrants issued as part of a PIPE transaction, for $3.50 per share and accompanying warrant. false 21 2734200 0 EF Hutton also received a cash fee equal to 1.0% of the gross proceeds raised by the Company in the Offering for non-accountable expenses, and $70,000 for accountable expenses. 0 false Pasithea Therapeutics Corp. /s/ Tiago Reis Marques Tiago Reis Marques Chief Executive Officer 2021-12-07